Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Parvimonas micra is associated with tumour immune profiles in molecular subtypes of colorectal cancer
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap, Patologi.
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap, Patologi.
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap, Patologi.
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap, Patologi.
Visa övriga samt affilieringar
2022 (Engelska)Ingår i: Cancer Immunology and Immunotherapy, ISSN 0340-7004, E-ISSN 1432-0851, Vol. 71, s. 2565-2575Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

The importance of the tumour microbiome in different aspects of colorectal cancer (CRC) has been increasingly recognised, but many questions remain. The aim of this study was to explore the effect of specific CRC associated microbes on the tumour immune response, which has a considerable prognostic value in CRC. We applied specific qPCR to detect Parvimonas micra and Fusobacterium nucleatum in tumour tissues from an immunologically well-characterised cohort of 69 CRC patients. This cohort included detailed analyses of immune profiles based on flow cytometry and transcriptomics in tumour tissue and blood, along with comprehensive analyses of molecular subtypes. P. micra and F. nucleatum were detected in 24% and 64% of tumour tissues, respectively. We found a significant association of P. micra with high-grade tumours and tumours of CMS1 subtype. F. nucleatum was significantly associated with right-sided tumours, microsatellite instability, and CMS1 tumours. The immunological analyses revealed significant associations of P. micra with activated CD69+ T lymphocytes and increased antigen-presenting HLA-DR+ B lymphocytes. P. micra was also positively associated with M1 and M2 macrophage traits. The impact of P. micra tumour colonisation on the immune response was further assessed using transcriptomics in validation of our findings. No associations were found between F. nucleatum and immune profiles in this study. Our findings support novel associations between P. micra and the immune response in CRC. A better understanding of these interactions might help to identify important predictive and prognostic tools as well as new targets for therapy.

Ort, förlag, år, upplaga, sidor
Springer, 2022. Vol. 71, s. 2565-2575
Nyckelord [en]
Colorectal cancer, F. nucleatum, Immunity, Mucosal microbiota, P. micra
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:umu:diva-193335DOI: 10.1007/s00262-022-03179-4ISI: 000770199300001PubMedID: 35301576Scopus ID: 2-s2.0-85126450770OAI: oai:DiVA.org:umu-193335DiVA, id: diva2:1647763
Forskningsfinansiär
Cancerforskningsfonden i Norrland, AMP 21-1048Region Västerbotten, VLL-833541Cancerfonden, 20 1271PjFTillgänglig från: 2022-03-28 Skapad: 2022-03-28 Senast uppdaterad: 2024-03-26Bibliografiskt granskad
Ingår i avhandling
1. Gut microbiota in colorectal cancer: The importance of Parvimonas micra
Öppna denna publikation i ny flik eller fönster >>Gut microbiota in colorectal cancer: The importance of Parvimonas micra
2024 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Alternativ titel[sv]
Tarmfloran hos patienter med kolorektalcancer : betydelsen av Parvimonas micra
Abstract [en]

Colorectal cancer (CRC) is a heterogenous disease consisting of multiple molecular subtypes, each of which has diverse treatment responses and prognoses. The importance of the gut microbiota in CRC development and progression has undergone increasing recognition in recent years, with a structural segregation in terms of microbial composition between CRC patients and healthy controls. However, many questions remain before a full understanding of the impact of the gut microbiota on CRC is reached. The overall aim of this thesis was to explore the role of gut microbes in CRC, including their potential as CRC biomarkers and associations with clinicopathological, immunological, and molecular traits of CRC. A particular focus was the CRC-associated oral pathogen Parvimonas micra.

To investigate faecal microbiota as a potential biomarker for CRC, we studied the presence of specific bacteria in faeces from CRC patients and controls using qPCR. We found higher levels of P. micra in faecal samples from CRC patients than from control patients. A test for high levels of P. micra was able to identify CRC with a specificity of 87.3% and a sensitivity of 60.5%. Adding the oral pathogen Fusobacterium nucleatum, colibactin-producing bacteria, and faecal haemoglobin to the test enhanced its sensitivity.

We further aimed to explore the associations of P. micra and F. nucleatum with molecular subtypes of CRC and the tumour immune response. The levels of P. micra and F. nucleatum, as analysed by qPCR in both faeces and tumour tissue from CRC patients, were found to be positively correlated. High levels of intratumoural P. micra and F. nucleatum were associated with tumours of the microsatellite instable subtype and BRAF-mutated tumours. For F. nucleatum, an additional association with right-sided tumours was found. Moreover, both P. micra and F. nucleatum in tumour tissue were associated with the immune-activated consensus molecular subtype (CMS) 1 subtype of CRC. In line with this finding, we found novel associations between intratumoural P. micra and specific immune traits, which were evaluated by flow cytometry, indicating an active immune response in CRC. These results were further confirmed using transcriptomics. However, no associations with specific immune traits were found for F. nucleatum.

We also investigated associations between faecal and intratumoural levels of P. micra and F. nucleatum and survival in CRC patients. CRC patients with high levels of intratumoural P. micra and F. nucleatum showed reduced five-year cancer-specific survival. This association remained significant for P. micra in multivariable analysis. No associations with cancer-specific survival were found for levels of P. micra and F. nucleatum in faeces.

To investigate the faecal microbial landscape of CRC patients on a larger scale, we used 16S rRNA sequencing. Network analysis revealed a cluster of associated bacteria, including P. micra and F. nucleatum, as well as other CRC-related pathogens such as Bacteroides fragilis, Peptostreptococcus stomatitis, and Porphyromonas spp. Furthermore, beta-diversity analysis indicated a significantly different gut microbial composition depending on tumour location and microsatellite instability status. Interestingly, three of the six annotated species most strongly associated with microsatellite instable tumours were also present in the cluster: P. micra, F. nucleatum, and P. stomatis.

In conclusion, our results suggest P. micra as a putative candidate for a future non-invasive microbial test panel for detection of CRC. Moreover, our results indicate that intratumoural P. micra and F. nucleatum are associated with immune-active subtypes of CRC, including microsatellite instable tumours and tumours of the CMS1 subtype, as well as decreased patient survival. Furthermore, P. micra and F. nucleatum were found to be associated with a cluster of other CRC-related oral pathogens. An improved understanding of the role of the gut microbiota in tumour progression may lead to the identification of important biomarkers for CRC disease and outcome, as well as potential targets for future therapy.

Ort, förlag, år, upplaga, sidor
Umeå: Umeå University, 2024. s. 53
Serie
Umeå University medical dissertations, ISSN 0346-6612 ; 2286
Nyckelord
Colorectal cancer, mucosal microbiota, Parvimonas micra, Fusobacterium nucleatum, immunity, survival
Nationell ämneskategori
Biomedicinsk laboratorievetenskap/teknologi
Forskningsämne
biomedicinsk laboratorievetenskap
Identifikatorer
urn:nbn:se:umu:diva-222737 (URN)978-91-8070-300-0 (ISBN)978-91-8070-299-7 (ISBN)
Disputation
2024-04-26, Hörsal Betula, byggnad 6M, Umeå, 13:00 (Engelska)
Opponent
Handledare
Tillgänglig från: 2024-04-05 Skapad: 2024-03-26 Senast uppdaterad: 2024-03-28Bibliografiskt granskad

Open Access i DiVA

fulltext(908 kB)133 nedladdningar
Filinformation
Filnamn FULLTEXT02.pdfFilstorlek 908 kBChecksumma SHA-512
7a0965157e29d267da257a7e9111b62a5b49c09d7e415b57bb3c55f1327208e6487d009dddb37f17cade88795e4ca9d4c55bb37bbcaca5c6a3d3ba6f741bb154
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Löwenmark, ThyraLi, XingruLöfgren Burström, AnnaZingmark, CarlLing, AgnesKellgren, Therese G.Larsson, PärLjuslinder, IngridWai, Sun NyuntEdin, SofiaPalmqvist, Richard

Sök vidare i DiVA

Av författaren/redaktören
Löwenmark, ThyraLi, XingruLöfgren Burström, AnnaZingmark, CarlLing, AgnesKellgren, Therese G.Larsson, PärLjuslinder, IngridWai, Sun NyuntEdin, SofiaPalmqvist, Richard
Av organisationen
PatologiAvdelningen för medicinOnkologiInstitutionen för molekylärbiologi (Medicinska fakulteten)
I samma tidskrift
Cancer Immunology and Immunotherapy
Cancer och onkologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 160 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 522 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf